Literature DB >> 16123302

Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.

Guangyong Peng1, Zhong Guo, Yukiko Kiniwa, Kui Shin Voo, Weiyi Peng, Tihui Fu, Daniel Y Wang, Yanchun Li, Helen Y Wang, Rong-Fu Wang.   

Abstract

CD4+ regulatory T (Treg) cells have a profound ability to suppress host immune responses, yet little is understood about how these cells are regulated. We describe a mechanism linking Toll-like receptor (TLR) 8 signaling to the control of Treg cell function, in which synthetic and natural ligands for human TLR8 can reverse Treg cell function. This effect was independent of dendritic cells but required functional TLR8-MyD88-IRAK4 signaling in Treg cells. Adoptive transfer of TLR8 ligand-stimulated Treg cells into tumor-bearing mice enhanced anti-tumor immunity. These results suggest that TLR8 signaling could play a critical role in controlling immune responses to cancer and other diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123302     DOI: 10.1126/science.1113401

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  257 in total

1.  Microbial infection-induced expansion of effector T cells overcomes the suppressive effects of regulatory T cells via an IL-2 deprivation mechanism.

Authors:  Alicia Benson; Sean Murray; Prashanthi Divakar; Nikolay Burnaevskiy; Reed Pifer; James Forman; Felix Yarovinsky
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

2.  Engagement of TLR2 reverses the suppressor function of conjunctiva CD4+CD25+ regulatory T cells and promotes herpes simplex virus epitope-specific CD4+CD25- effector T cell responses.

Authors:  Gargi Dasgupta; Aziz Alami Chentoufi; Sylvaine You; Payam Falatoonzadeh; Lourie Ann A Urbano; Ayesha Akhtarmalik; Kimberly Nguyen; Lilit Ablabutyan; Anthony B Nesburn; Lbachir BenMohamed
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-17       Impact factor: 4.799

3.  Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion.

Authors:  Yong Chan Kim; Ravikiran Bhairavabhotla; Jeongheon Yoon; Amit Golding; Angela M Thornton; Dat Q Tran; Ethan M Shevach
Journal:  Blood       Date:  2012-01-31       Impact factor: 22.113

4.  Plasmacytoid dendritic cells lead the charge against tumors.

Authors:  Sonia Jiménez-Baranda; Inês Pires Silva; Nina Bhardwaj
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

5.  Pathogenic and protective roles of MyD88 in leukocytes and epithelial cells in mouse models of inflammatory bowel disease.

Authors:  Mark J Asquith; Olivier Boulard; Fiona Powrie; Kevin J Maloy
Journal:  Gastroenterology       Date:  2010-04-28       Impact factor: 22.682

6.  Human regulatory T cells induce T-lymphocyte senescence.

Authors:  Jian Ye; Xingxu Huang; Eddy C Hsueh; Qunyuan Zhang; Chunling Ma; Yanping Zhang; Mark A Varvares; Daniel F Hoft; Guangyong Peng
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

Review 7.  The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?

Authors:  Craig L Slingluff
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

8.  Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer.

Authors:  Chunling Ma; Qunyuan Zhang; Jian Ye; Fang Wang; Yanping Zhang; Eric Wevers; Theresa Schwartz; Pamela Hunborg; Mark A Varvares; Daniel F Hoft; Eddy C Hsueh; Guangyong Peng
Journal:  J Immunol       Date:  2012-10-03       Impact factor: 5.422

9.  The choice of linker for conjugating R848 to inactivated influenza virus determines the stimulatory capacity for innate immune cells.

Authors:  Marlena M Westcott; Elene A Clemens; Beth C Holbrook; S Bruce King; Martha A Alexander-Miller
Journal:  Vaccine       Date:  2018-02-21       Impact factor: 3.641

Review 10.  Ubiquitous points of control over regulatory T cells.

Authors:  Fan Pan; Joseph Barbi
Journal:  J Mol Med (Berl)       Date:  2014-04-29       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.